We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ECCMID Congress Name Changes to ESCMID Global

By LabMedica International staff writers
Posted on 11 Apr 2024

Over the last few years, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) has evolved remarkably. More...

The society is now stronger and broader than ever before in the four decades since it was founded. Currently, ESCMID is focusing on stepping up the fight against antimicrobial resistance, advancing preparedness for emerging infections, and leading in the practice, education, and training of specialists. In recent years, ESCMID has welcomed over 4000 new members and expects to see a record-breaking 20,000 colleagues attend its congress in Barcelona. Hence, the organization feels the need to adapt to this new reality.

In 2023, ESCMID’s in-depth analysis of its brand and communication efforts revealed that the brand failed to adequately reflect ESCMID’s expanding global role. The analysis also revealed that most community members were unaware of various activities undertaken by ESCMID related to research, education, and guidelines. Additionally, most of its audience was unaware of the connection between the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and ESCMID. As a result, the society has now decided to strengthen its main brand, ESCMID, and bring all of its various sub-brands more closely together under one large ESCMID umbrella. This includes changing the name of its congress to “ESCMID Global”, creating a clear link to ESCMID, and conveying its outreach and perspective beyond Europe.

Simultaneously, ESCMID is modernizing its visual identity. As the society strives for pioneering research and state-of-the-art education, it also aims to communicate in an effective manner that will be suitable to the present time and also apt for the next decade. As a first step in these efforts, the organization has released its renewed website escmid.org. The upcoming ESCMID Global, formerly ECCMID, in Barcelona (27–30 April 2024) will be the society’s 34th congress and the first one with the new name and look.

Related Links:
ESCMID


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.